For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Robert F. Kennedy Jr. dismissed all members of the CDC’s Advisory Committee on Immunization Practices, which recommends which ...

F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring 'razor ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

Moderna announced that its experimental shot was nearly 84 percent effective at preventing respiratory syncytial virus symptoms in a large study of adults 60 years and older. The drugmaker plans to ...

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $27.35. Co ...

Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Moderna (MRNA – Research Report) today and set a price target of $69.00. The company’s shares closed yesterday ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Cassidy’s Kennedy quagmire The Trump ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

In other developments, the ECDC today reported a slow rise in COVID activity in the Europe, which may partly reflect waning ...